Mass spectrometry biomolecular omics profiling and imaging to dissect the initial emergence of molecular drug resistance in ALK-positive (ALK+) lung cancer.

12018Background: ALK tyrosine kinase inhibitors (TKIs) yield a significant tumor response in advanced ALK+ non-small cell lung cancer (NSCLC), that is often rapid and remarkable. Nonetheless, acqui...